Relmada Therapeutics, Inc.(RLMD)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Relmada Therapeutics remains a high-risk, clinical-stage entity entirely dependent on external capital to fund its RELIANCE-II program, as it currently lacks any commercial revenue streams.
• The company's reliance on stock-based compensation, which reached $3.2 million in 2025Q4, masks the underlying economic cost of its R&D-heavy business model.
• Investors should remain cautious as the firm's history of massive retained earnings deficits, totaling $717.3 million, suggests a structural inability to achieve self-sustaining profitability without further dilutive financing.